MicroVision MOVIA lidar gains support on NVIDIA DRIVE AGX platform
H.C. Wainwright reiterated its Buy rating and $16.00 price target on Brainsway (TASE:BWAY) (NASDAQ:BWAY), a $214 million medical device company with impressive 27% revenue growth and 75% gross margins, following the company’s announcement of preliminary results from a multicenter trial of its accelerated Deep Transcranial Magnetic Stimulation (Deep TMS) protocol. According to InvestingPro, the company maintains a "GREAT" financial health score.
The trial, described as the largest randomized, controlled, blinded, multi-center study of an accelerated Deep TMS protocol, enrolled 104 adult patients diagnosed with major depressive disorder (MDD) across eight sites. Patients were divided into two active treatment groups comparing the standard Deep TMS protocol against an accelerated version. InvestingPro data shows the stock has gained nearly 88% over the past year, with 12 more exclusive ProTips available to subscribers.
Results indicated that the accelerated Deep TMS protocol using intermittent theta burst stimulation (iTBS) achieved comparable outcomes to the standard once-daily TMS protocol while "requiring considerably fewer visits to the clinic," according to the company’s press release. With the stock trading near its 52-week high, investors can access comprehensive analysis and Fair Value estimates through InvestingPro’s detailed research reports, available for over 1,400 US stocks.
Patients in the accelerated group completed five sessions per day over six treatment days, followed by a continuation phase of eight sessions over the subsequent four weeks. This approach was specifically designed to reduce treatment burden for patients seeking depression therapy.
The study measured change in depressive symptoms using the HDRS-21 scale as its primary endpoint, with response and remission rates serving as secondary endpoints. H.C. Wainwright maintained its 12-month price target of $16 for Brainsway stock following these results.
In other recent news, BrainsWay reported first-quarter revenues of $11.5 million, closely aligning with H.C. Wainwright’s projection of $11.3 million. The company achieved net earnings of $0.03 per share for the first quarter, consistent with analysts’ estimates. BrainsWay has maintained its revenue guidance for the year within the range of $49-51 million and ended the first quarter with $71.6 million in cash, cash equivalents, and short-term deposits. Additionally, H.C. Wainwright has maintained a Buy rating and a $16.00 price target on BrainsWay stock, reflecting confidence in the company’s strategic growth initiatives.
The company recently announced a $5 million strategic equity investment in Stella MSO, LLC, securing a minority stake in the management services organization. This investment is part of BrainsWay’s broader strategy to enhance the reach of its Deep Transcranial Magnetic Stimulation (Deep TMS) Therapy. Preliminary results from a multicenter trial suggest that an accelerated Deep TMS protocol for major depressive disorder shows comparable efficacy to standard treatment. However, the accelerated protocol remains investigational and is not yet FDA-cleared. BrainsWay continues to conduct clinical trials and is preparing to launch its next-generation Deep TMS 360 system.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.